52 related articles for article (PubMed ID: 22317951)
1. Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer.
Gass P; Thiel FC; Häberle L; Ackermann S; Theuser AK; Hummel N; Boehm S; Kimmig R; Reinthaller A; Becker S; Hilpert F; Janni W; Vergote I; Harter P; Emons J; Hein A; Beckmann MW; Fasching PA; Pöschke P;
Gynecol Oncol; 2024 Apr; 183():25-32. PubMed ID: 38490057
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study.
Coleman RL; Hu W; Soliman P; Nick A; Ramirez PT; Westin SN; Garcia ME; Zhu Z; Palancia J; Fellman BM; Yuan Y; Ram P; Bischoff F; Schmeler K; Bodurka D; Meyer LA; Sood AK
Gynecol Oncol; 2021 Apr; 161(1):104-112. PubMed ID: 33551196
[TBL] [Abstract][Full Text] [Related]
3. Prior treatment with oxaliplatin-containing regimens and higher total bilirubin levels are risk factors for neutropenia and febrile neutropenia in patients with gastric or esophagogastric junction cancer receiving weekly paclitaxel and ramucirumab therapy: a single center retrospective study.
Nara K; Yamamoto T; Yamashita H; Yagi K; Takada T; Seto Y; Suzuki H
BMC Cancer; 2023 Oct; 23(1):979. PubMed ID: 37833660
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix.
Frumovitz M; Munsell MF; Burzawa JK; Byers LA; Ramalingam P; Brown J; Coleman RL
Gynecol Oncol; 2017 Jan; 144(1):46-50. PubMed ID: 27823771
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Paclitaxel plus Carboplatin versus Observation in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck.
Fukuda N; Oki R; Suto H; Wang X; Urasaki T; Sato Y; Nakano K; Yunokawa M; Ono M; Tomomatsu J; Mitani H; Takahashi S
Oncology; 2023; 101(8):502-511. PubMed ID: 37429272
[TBL] [Abstract][Full Text] [Related]
6. A comparison of two chemotherapy regimens in advanced, recurrent, or metastatic salivary gland carcinoma.
Ameri A; Sourati A; Behzadi B; Lesan M; Taghizadeh-Hesary F
Indian J Cancer; 2023; 60(3):418-426. PubMed ID: 36861690
[TBL] [Abstract][Full Text] [Related]
7. Combination Treatment With Paclitaxel, Carboplatin, and Cetuximab (PCE) as First-Line Treatment in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma.
Ueda Y; Enokida T; Okano S; Fujisawa T; Ito K; Tahara M
Front Oncol; 2020; 10():571304. PubMed ID: 33117701
[No Abstract] [Full Text] [Related]
8. Patient profiles, treatment patterns, and outcomes among persistent, recurrent, or metastatic cervical cancer patients under routine care in the United States.
Gokhale M; Yu R; Monberg M; Tekin C; Chen L; DeClue RW; Knapp K; Lal LS
Cancer Treat Res Commun; 2023; 36():100726. PubMed ID: 37301127
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel and Carboplatin in Combination with Low-intensity Pulsed Ultrasound for Glioblastoma.
Habashy KJ; Dmello C; Chen L; Arrieta VA; Kim KS; Gould A; Youngblood MW; Bouchoux G; Burdett KB; Zhang H; Canney M; Stupp R; Sonabend AM
Clin Cancer Res; 2024 Apr; 30(8):1619-1629. PubMed ID: 38295144
[TBL] [Abstract][Full Text] [Related]
10. Retreatment with carboplatin and paclitaxel for recurrent endometrial cancer: A retrospective study of the Memorial Sloan Kettering Cancer Center experience.
Rubinstein M; Halpenny D; Makker V; Grisham RN; Aghajanian C; Cadoo K
Gynecol Oncol Rep; 2019 May; 28():120-123. PubMed ID: 31011610
[TBL] [Abstract][Full Text] [Related]
11. Investigating the clinical impact of dose-banding for weekly paclitaxel in patients with breast cancer: A retrospective and monocentric study.
Puisset F; Le Louedec F; Dalenc F; Verguet L; De Maio E; Lacaze JL; Montastruc M; Ung M; Vinson C; Perriat S; Pacher S; Chatelut E; Koning MW
Br J Clin Pharmacol; 2023 Jul; 89(7):2283-2294. PubMed ID: 36854898
[TBL] [Abstract][Full Text] [Related]
12. Improving survival from metastatic, recurrent, or persistent cervical cancer.
Mileshkin LR; Manoharan S
Lancet; 2024 Jan; 403(10421):2-4. PubMed ID: 38048788
[No Abstract] [Full Text] [Related]
13. Efficacy of Modified Dose-dense Paclitaxel in Recurrent Cervical Cancer.
Machida H; Moeini A; Ciccone MA; Mostofizadeh S; Takiuchi T; Brunette LL; Roman LD; Matsuo K
Am J Clin Oncol; 2018 Sep; 41(9):851-860. PubMed ID: 28763329
[TBL] [Abstract][Full Text] [Related]
14. NMK-TD-100, a novel microtubule modulating agent, blocks mitosis and induces apoptosis in HeLa cells by binding to tubulin.
Bhattacharya S; Kumar NM; Ganguli A; Tantak MP; Kumar D; Chakrabarti G
PLoS One; 2013; 8(10):e76286. PubMed ID: 24116100
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of paclitaxel/carboplatin in a dose dense or weekly regimen in 66 patients with recurrent or primary metastatic cervical cancer.
Torfs S; Cadron I; Amant F; Leunen K; Berteloot P; Vergote I
Eur J Cancer; 2012 Jun; 48(9):1332-40. PubMed ID: 22317951
[TBL] [Abstract][Full Text] [Related]
16. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
[TBL] [Abstract][Full Text] [Related]
17. The "Leuven" dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer.
Cadron I; Leunen K; Amant F; Van Gorp T; Neven P; Vergote I
Gynecol Oncol; 2007 Aug; 106(2):354-61. PubMed ID: 17499348
[TBL] [Abstract][Full Text] [Related]
18. Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: the British Columbia Cancer Agency experience.
Tinker AV; Bhagat K; Swenerton KD; Hoskins PJ
Gynecol Oncol; 2005 Jul; 98(1):54-8. PubMed ID: 15904950
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza.
Zanetta G; Fei F; Mangioni C
Semin Oncol; 2000 Feb; 27(1 Suppl 1):23-7. PubMed ID: 10697040
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
